Symbravo for Migraine: Combination Tablet and Safety

Symbravo is a prescription tablet combining rizatriptan, a triptan, with meloxicam, a nonsteroidal anti-inflammatory drug, or NSAID. The FDA approved it in 2025 for the acute treatment of migraine with or without aura in adults. [2] It treats an attack rather than preventing future attacks. [3]

Combining two medicine classes can be worth discussing when an attack plan provides incomplete relief. Symbravo also brings the precautions of both components. A treatment decision needs to account for your heart and circulation history, stomach and kidney health, other medicines, and pregnancy plans.

Why combine a triptan and an NSAID?

Rizatriptan acts on serotonin receptors involved in migraine signaling. Meloxicam affects prostaglandin production, part of the body's pain and inflammation pathways. The combination uses these different actions in a single tablet. [6]

International Headache Society recommendations include a triptan and NSAID combination as an option when an individual acute treatment is insufficient. [7] That general approach does not make every combination appropriate for every person. For example, a reason to avoid an NSAID still matters when the NSAID is packaged with a triptan.

Explain what you would like to improve: getting enough relief to work, avoiding pain returning later, or finding a plan you can follow consistently. “Stronger medicine” is less useful than describing the outcome you need. Read medicines for attacks versus prevention for how this fits into the larger plan.

What the Symbravo studies assessed

The MOMENTUM trial studied the combination under its development name, AXS-07, in people reporting inadequate benefit from earlier acute treatments. Participants were randomized to the combination, its individual components, or placebo. Outcomes included complete pain freedom, associated symptom relief, and sustained response. [5]

The separate INTERCEPT trial compared the combination with placebo when treatment was taken early during mild headache pain. In that trial, about 33% receiving the combination were pain free at two hours, compared with about 16% receiving placebo. [6]

These are results from particular study populations and treatment conditions. They support the medicine's effectiveness but do not promise that it will work after your previous prescription did not. Nor do they establish that it is the best acute medicine for everyone. Pain freedom means no headache pain at the assessment time; it is a different outcome from partial improvement or returning to normal activities.

The boxed heart, stroke, and gastrointestinal warnings

Symbravo carries boxed warnings about serious cardiovascular and gastrointestinal events. NSAIDs can increase the risk of heart attack or stroke, including early in treatment. They can also cause stomach or intestinal bleeding, ulcers, or perforation, sometimes without warning. Older adults and people with prior ulcers or gastrointestinal bleeding have greater gastrointestinal risk. [3]

Contraindications include coronary disease or coronary spasm, stroke or TIA, peripheral vascular or ischemic bowel disease, uncontrolled high blood pressure, use around coronary bypass surgery, hemiplegic or basilar migraine, and relevant drug or NSAID allergies. [1]

Tell the clinician about prior aspirin-related asthma or allergic reactions.

Get emergency help for chest pain, stroke-like symptoms, severe breathing difficulty, or facial or throat swelling. Black stools or vomiting blood also require urgent care. [3] Do not treat a new neurological symptom as routine migraine without evaluation.

Kidney health, pregnancy, and breastfeeding

Symbravo is not recommended with moderate to severe kidney impairment. It is contraindicated when that impairment is accompanied by volume depletion that creates a risk of kidney failure, and in people requiring dialysis. [1]

Mention kidney disease, dehydration, vomiting, and medicines for blood pressure or fluid retention before treatment.

FDA guidance advises avoiding NSAIDs from about 20 weeks of pregnancy unless specifically directed by a clinician. They can impair fetal kidney function and reduce amniotic fluid. At about 30 weeks and later, they should be avoided because of additional fetal circulation risks. Any necessary use between those periods requires clinical oversight. [4]

Review pregnancy, attempts to conceive, and breastfeeding before a prescription decision. Do not assume that previous use of rizatriptan alone answers the safety question for a product that also contains meloxicam. If prescribed low-dose aspirin for pregnancy or another condition, do not stop it yourself; ask the prescribing clinician to coordinate the plan.

Important interactions to review

Symbravo is contraindicated with propranolol. It must not be used within 24 hours of another triptan or ergot-type medicine, or with an MAO-A inhibitor, including a nonselective MAO inhibitor, or within two weeks of stopping one. [1]

Tell the clinician about all migraine attack and preventive prescriptions.

Do not add ibuprofen, naproxen, aspirin, or another NSAID without checking the plan. Blood thinners and some antidepressants can increase bleeding risk. [10] Serotonergic medicines also require review for serotonin syndrome. [9] Include cold, pain, and sleep products because their ingredient lists may contain another NSAID. [3]

The label also states that Symbravo is not interchangeable with separate meloxicam and rizatriptan products, even at similar milligram strengths. [1]

Do not recreate the combination from leftover prescriptions or substitute medicines yourself.

A checklist for your treatment discussion

• Bring the names, timing, benefits, and side effects of previous attack medicines.
• List propranolol, antidepressants, aspirin, blood thinners, and all nonprescription products.
• Describe heart, stroke, blood pressure, ulcer, bleeding, kidney, and allergy history.
• Mention pregnancy plans and breastfeeding, even if the visit is about migraine.
• Ask for a written backup plan if pain persists or returns.
• Agree on what to record and when treatment will be reviewed.

Track each treatment and how it affects pain, associated symptoms, activities, and later recurrence. Note dizziness or sleepiness, which are recognized side effects. [8] Bring the record to follow-up so the discussion reflects your experience rather than a single memorable attack.

Frequently asked questions about Symbravo

Can I take another tablet if the first one does not work?

The labeled maximum is one tablet daily; the safety and effectiveness of a second dose for the same attack have not been established. Safety of treating, on average, more than seven headaches in 30 days has not been established. [1]

Ask for the next step in advance rather than adding a dose.

Does taking it with food remove the bleeding risk?

No. Food does not remove the serious gastrointestinal warning. [3] A history of ulcers or bleeding belongs in the safety review even if you usually take medicines with a meal.

Discussing Symbravo with TeleHeadache

TeleHeadache offers online assessment for eligible adults age 18 and older who are physically located in Florida and may prescribe when clinically appropriate. Clinical care can review whether this combination fits your attack history and safety needs. Pharmacy medication costs are separate from clinical care costs. Insurance coverage, prior authorization, and the final treatment choice depend on your situation.

Official medication information and further reading

Official Symbravo website · Symbravo on Drugs.com · Drugs.com

Use the current U.S. prescribing information and your own prescription instructions when discussing this medicine with your clinician or pharmacist.

Educational information supports a discussion with your clinician and does not replace individualized medical evaluation. Medication choice and prescribing require clinical review.